法国新创公司Tissium开发了一种由脂肪酸和甘油制成的生物聚合物液体，可在光照下黏附组织，用于替代或辅助传统的医疗缝合线来修复受损的周边神经。这种液体如同夹板般固定断裂的神经末端，待组织自行愈合后便会自然降解，使神经完整恢复。在美国进行的12名手指神经损伤患者临床试验中，所有患者均恢复了温度、疼痛、质地和轻触的感知能力，且一年后无人出现疼痛或装置相关并发症。

Tissium已从创投公司和家族办公室筹集了3000万欧元的私人投资，并从欧洲投资银行获得3000万欧元的债务融资，以扩大商业化规模。该产品去年已获得美国FDA上市许可，目前美国外科医师已可购买使用。公司将继续在法国北部进行生产制造。

除了周边神经修复，Tissium正将该技术拓展至其他医疗领域。公司计划在美国招募约200名患者进行疝气修复临床试验，利用其生物聚合物提供更一致的手术效果，以改善患者的恢复过程并降低疝气复发率。此外，Tissium也在开发心血管重建产品，这是创办人Pereira近20年前攻读生物工程博士时最初构想的应用方向，公司正准备在美国启动随机关键性临床试验。

French startup Tissium has developed a biopolymer liquid made from fatty acid and glycerol that adheres to tissue when exposed to light, serving as a splint to hold severed peripheral nerves in place during self-repair before biodegrading. In a US clinical trial involving 12 patients with finger nerve injuries, all participants regained sensation—including temperature, pain, texture, and light touch—with no pain or device-related complications reported after one year, outperforming the roughly 80 percent success rate of conventional micro-suture techniques.

The company has secured €30 million in private venture capital investment and an additional €30 million in debt financing from the European Investment Bank to scale commercialization. Its product received FDA marketing approval last year and is already available for purchase by surgeons in the United States, with manufacturing continuing at its facility in northern France. (Key numbers: 3000)

Beyond nerve repair, Tissium is expanding into hernia treatment, planning to enroll approximately 200 patients in a US trial where its biopolymer would improve surgical consistency and patient recovery outcomes. The company is also advancing its original vision of cardiovascular reconstruction, preparing to launch a randomized pivotal trial in the US for a cardiovascular product, supported by the newly raised funding.